Lucid Diagnostics Strengthens Leadership with Danielle Scelfo
Lucid Diagnostics Welcomes Danielle Scelfo as Senior Vice President
Danielle Scelfo has joined Lucid Diagnostics Inc. as the Senior Vice President of Market Access & Government Affairs. Her appointment comes at a pivotal time as the company prepares to enhance its market access infrastructure and broaden commercial coverage for its innovative EsoGuard Esophageal DNA Test.
Strategic Enhancements in Market Access
Scelfo’s extensive experience in the diagnostics sector spans over 25 years, focusing on market access, reimbursement, and health policy. Her role will be crucial in navigating Lucid through key reimbursement milestones, particularly in advancing Medicare coverage for the EsoGuard test. This initiative is critical not only for Lucid but also for improving patient access to essential diagnostic services.
In her new role, Scelfo will oversee activities geared toward payer engagement and will ensure that the Lucid team is well-positioned to meet the increasing demands for effective esophageal cancer prevention tools. Her proven track record in securing broad coverage for molecular diagnostic tests will be instrumental in fulfilling Lucid’s aspirations.
Positive Projections for EsoGuard
Lucid Diagnostics, which operates under the stock ticker Nasdaq: LUCD, believes that the recent feedback from the Medicare MolDX CAC meeting paves the way for Medicare coverage approval. This significant development strengthens the company's confidence in their market approach, facilitating ongoing discussions with commercial insurers to broaden access to the EsoGuard test.
“Danielle’s experience and strategic focus align perfectly with our goals as we amplify efforts to offer the EsoGuard test, which could make a monumental difference for patients at risk of esophageal cancer,” said Lishan Aklog, M.D., the CEO of Lucid Diagnostics. “Her addition to our team comes at a crucial time, and we expect her insights will enhance our efforts in establishing market presence,” added Aklog.
Danielle Scelfo's Notable Career
Before joining Lucid, Scelfo served as Vice President of Market Access & Health Policy at ClearNote Health, a company dedicated to advancing cancer detection through innovative blood tests. Her career also includes significant roles at CareDx, Hologic, Adaptive Biotechnologies, and Genomic Health. Her leadership in prominent industry organizations has also aided in developing pivotal policies enhancing reimbursement solutions in diagnostics.
Paving the Path Forward
With her on board, Lucid aims to solidify its infrastructure for insurance coverage, ensuring every patient has access to the essential tests and treatments they deserve. Scelfo expressed excitement about joining Lucid at this critical moment, stating she looks forward to leveraging the strong clinical evidence supporting EsoGuard’s effectiveness in early detection.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a leader in cancer prevention medical diagnostics, operating as a subsidiary of PAVmed Inc. (Nasdaq: PAVM). The company is dedicated to serving the substantial population of patients suffering from gastroesophageal reflux disease (GERD), who are at heightened risk of progressing to esophageal precancer and cancer. Lucid's innovative EsoGuard test is designed to facilitate early detection of esophageal conditions, aiming to prevent cancer through rapid analysis of DNA samples obtained via a noninvasive procedure.
Frequently Asked Questions
What position has Danielle Scelfo been appointed to at Lucid Diagnostics?
Danielle Scelfo has been appointed as Senior Vice President of Market Access & Government Affairs at Lucid Diagnostics.
What is the key focus of Danielle Scelfo's role?
Scelfo will focus on enhancing market access strategies and securing insurance coverage for Lucid's EsoGuard Esophageal DNA Test.
How does Lucid Diagnostics plan to improve access to its EsoGuard test?
Lucid aims to advance Medicare coverage and engage with commercial insurers to ensure broad patient access to the EsoGuard test.
What is EsoGuard and its significance?
EsoGuard is an Esophageal DNA Test developed for early detection of esophageal precancer, offering patients vital insights and prevention options.
What is Lucid Diagnostics dedicated to accomplishing?
Lucid Diagnostics is dedicated to preventing esophageal cancer through early detection and improving patient access to essential diagnostic testing.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.